Prospective study to quantify the prevalence of possible tardive dyskinesia (TD) in outpatient psychiatry practices in the United States (US), as well as to describe the associated disease burden in a cohort of patients with one or more psychiatric disorders and a cumulative lifetime exposure to antipsychotic medication of three months or more.

Inclusion Criteria:

• Patient has a cumulative lifetime exposure to antipsychotic medication of three months or more
• Patient has a clinician confirmed diagnosis of one or more psychiatric disorder(s), as defined in the DSM-5
• Patient has a usual care clinic visit scheduled during the study recruitment window (i.e. a pre-defined 2-week period)
• Patient is able to read and understand English
• Patient is willing and able to comply with the study requirements

Exclusion Criteria:

• Patient is unable to provide informed consent.

Patients must be 18 years or older with a cumulative lifetime exposure to antipsychotic medication of three months or more.